Announcements

CARDINAL Webex Meetings
Reata Pharmaceuticals will be hosting online Webex meetings to discuss recent CARDINAL Phase 2 data plus study updates and next steps for the ongoing Phase 3 portion of CARDINAL.

Contact Hanh Nguyen at Hanh.Nguyen@reatapharma.com for a link to join the meeting. The same information will be presented at both meetings, so pick the time that best fits your schedule:
  • Tuesday, September 12 at 10:00am PDT/1:00pm EDT
  • Thursday, September 14 at 5:00pm PST/8:00pm EDT

Don’t miss the Alport Family Meeting!
The Minneapolis family meeting on October 7-8 is a great opportunity to hear from experts, meet other patients and families, and find support. Adult, teen/young adult, and childcare options available. Register today!

Annual Campaign for Healthy Kidneys
The ASF Research Program is funded through donations made to the Annual Campaign for Healthy Kidneys, which is held each fall. Become a fundraiser or make a donation today toward this year’s campaign!

Announcing Research Funding
ASF, the Pedersen Family and the Kidney Foundation of Canada announced funding of $100,000 each for two Alport syndrome research projects.

Ask the Experts Webinar Series
ASF hosts a monthly webinar series where experts address topics of interest to the Alport syndrome community. Recordings of past webinars can be found on our website and the ASF YouTube channel.

Alport Syndrome Research Studies
The ATHENA observational study conducted by Regulus Therapeutics sought to learn more about the natural history of Alport syndrome. No medications were administered as part of the study.

The CARDINAL study is an interventional Phase 2/3 study conducted by Reata Pharmaceuticals to test the effectiveness of the drug bardoxolone methyl in treating chronic kidney disease caused by Alport syndrome. Final data from Phase 2 will be available in the second half of 2017. However, based on positive initial data, screening for Phase 3 was initiated in July 2017. Phase 3 is a double-blind placebo-controlled study.

The HERA study is an interventional Phase 2 clinical study conducted by Regulus Therapeutics. The study will evaluate the safety and effectiveness of an investigational drug called RG-012. The study is expected to begin recruiting in fall 2017.

ASTOR Patient Registry
Participating in the patient registry allows patients, family members, and physicians to be informed of new clinical studies and trials. Join today!

Support ASF While You Shop
Support ASF while you shop online at Amazon, Best Buy, Nike, and thousands of other stores, including the ASF Store. Learn how!

Stay Updated!
Register today to receive the ASF newsletter each month. Click to view the latest newsletter.

Translate »